Does IBRITUMOMAB TIUXETAN Cause Second primary malignancy? 25 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Second primary malignancy have been filed in association with IBRITUMOMAB TIUXETAN (Zevalin). This represents 4.1% of all adverse event reports for IBRITUMOMAB TIUXETAN.
25
Reports of Second primary malignancy with IBRITUMOMAB TIUXETAN
4.1%
of all IBRITUMOMAB TIUXETAN reports
11
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From IBRITUMOMAB TIUXETAN?
Of the 25 reports, 11 (44.0%) resulted in death, 1 (4.0%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IBRITUMOMAB TIUXETAN. However, 25 reports have been filed with the FAERS database.
What Other Side Effects Does IBRITUMOMAB TIUXETAN Cause?
Sepsis (123)
Meningitis tuberculous (111)
Off label use (83)
Thrombocytopenia (75)
Myelodysplastic syndrome (72)
Progressive multifocal leukoencephalopathy (62)
Mucosal inflammation (56)
Neutropenia (55)
Anaemia (53)
Febrile neutropenia (49)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which IBRITUMOMAB TIUXETAN Alternatives Have Lower Second primary malignancy Risk?
IBRITUMOMAB TIUXETAN vs IBRUTINIB
IBRITUMOMAB TIUXETAN vs IBUPROFEN
IBRITUMOMAB TIUXETAN vs IBUPROFEN LYSINE
IBRITUMOMAB TIUXETAN vs IBUPROFEN UNKNOWN PRODUCT
IBRITUMOMAB TIUXETAN vs IBUPROFEN\IBUPROFEN